EZH2, an epigenetic driver of prostate cancer | Zendy

Yeqing Angela Yang | Zendy; Jindan Yu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

EZH2, an epigenetic driver of prostate cancer

Author(s) -

Yeqing Angela Yang,

Jindan Yu

Publication year - 2013

Publication title -

protein and cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.973

H-Index - 63

eISSN - 1674-8018

pISSN - 1674-800X

DOI - 10.1007/s13238-013-2093-2

Subject(s) - ezh2 , prostate cancer , epigenetics , prc2 , context (archaeology) , biology , cancer , histone methyltransferase , effector , cancer research , genetics , immunology , paleontology , gene

The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research